Just when you thought it was a time for a summer news slowdown, Blue Shield CA lays down the gauntlet. Aiming to reimagine pharmacy services, the payer is completely rethinking its drug supply chain - and the vendors who provide the services moving from the integrated model to a something more decentralized where Blue Shield retains control.
read full article ›Peter Neumann and the team at Tufts analyze IRA's impact on the development of drugs for rare diseases and what's now known as the "single orphan conundrum." Their take: "Our analysis suggests that the potential foregone follow-on indication approvals for serious illness and unmet needs could be nontrivial."
read full article ›Important read from Matthew Herper at STAT that reminds readers of the shortcomings of our drug pricing system (and an amazing zen koan analogy). As our CEO Jeff Berkowitz likes to say, so many of us who work in market access "have been scarred by the disconnects in the US healthcare system."
read full article ›Are you curious about new solutions that empower Medicare patients to better afford their meds? Did you miss our July 19 webinar on RE Assist, an AI-based platform that helps solve the Medicare copay problem?
read full article ›With the advent of decentralized manufacturing and other tools to lower the cost of goods, new business models that empower centers of excellence to become manufacturers will emerge. The broader business question is which indications are best suited for not-for-profit institutions and which are best suited for biotech and pharma. And right now that is a pretty thorny question.
read full article ›We're hosting a webinar on RE Assist, a tool Real Endpoints has developed to help solve the Medicare copay challenge. RE Assist is compliant, comprehensive, timely, and flexible.
read full article ›Here at Real Endpoints we frequently talk about the "diagnostic testing crisis." The phrase is deliberately hyperbolic, but the point is that we have a wealth of targeted medicines that don't necessarily get to patients because said individuals don't get tested in the first place.
read full article ›With the recent approval of multiple gene therapies, including BioMarin's Roctavian for hemophilia A, there's never been a better time to get smart - or smarter - about warranties. Warranties are one of the emerging innovative contracting models that payers and life sciences companies are interested in using to drive access to curative therapies.
read full article ›As we roll into a holiday weekend, a spate of news stories underscores just how important it is to have a nuanced understanding of market access given the complexity of the US health care system.
read full article ›We're hosting a webinar on RE Assist, a tool Real Endpoints has developed to help solve the Medicare copay challenge. RE Assist is compliant, comprehensive, timely, and flexible.
read full article ›